Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company – investor.lilly.com

What Happened

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company  investor.lilly.comExclusive | Eli Lilly Strikes Deal for Cancer Biotech  WSJEli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion  CNBCLilly to buy Kelonia Therapeutics for up to $7 billion to boost cancer pipeline  ReutersLilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says  Yahoo

Why It Matters

This development may influence policy, markets, and public sentiment based on how events unfold.

Background Context

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company  investor.lilly.comExclusive | Eli Lilly Strikes Deal for Cancer Biotech  WSJEli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion  CNBCLilly to buy Kelonia Therapeutics for up to $7 billion to boost cancer pipeline  ReutersLilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says  Yahoo

What To Watch Next

Track official statements, independent verification, and regional impact updates in the next 24 to 48 hours.

Editorial Next Step

Add your local context, fact checks, quotes, and analysis before or after publication.

Source: Business – Latest – Google NewsOriginal Link

Source: Business – Latest – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *